This page shows the latest Trobalt news and features for those working in and with pharma, biotech and healthcare.
GSK/ Valeant's Trobalt set for EU restrictions. Eye concerns prompt CHMP to recommend last-line use for the epilepsy drug. ... European regulatory advisors have recommended GlaxoSmithKline and Valeant's epilepsy drug Trobalt be restricted after safety
Comparing uptake, however, both Zebinix and Vimpat had slow starts before achieving fast acceleration, whereas uptake for Trobalt was “ very, very slow” according to Hendler.
In May 2011, GlaxoSmithKline launched its new epilepsy medicine Trobalt in the UK.
In the EU, ezogabine is known as retigabine (Trobalt). The drug received marketing authorisation in the EU in March 2011.
GSK launches first-in-class epilepsy drug. GSK introduces Trobalt for the adjunct treatment of adults with partial-onset seizures. ... GlaxoSmithKline (GSK) has launched Trobalt (retigabine), the first in a new class of anti-epileptic drug (AED), for the
Recent approvals for GSK include lupus drug Benlysta (belimumab), Horizant (gabapentin enacarbil) for Restless Legs Syndrome and epilepsy treatment Trobalt (retigabine).
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Committee and the same 'no proof' decision was reached regarding GlaxoSmithKline's Trobalt (retigabine) for epilepsy.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...